The Effect of Ondansetron on Decreasing the Hospitalization Rate in Children with Gastroenteritis and Recurrent Vomiting
Abstract
Background: Diarrhea is one of the most common disorders in infancy and childhood and recurrent vomiting is a main reason for \nhospitalization for these patients. This study was to assess the effect of injective ondansetron on decreasing the hospitalization rate \nin children with diarrhea and recurrent vomiting. \nMethods: In this clinical trial study, patients between six months and six years, with acute viral diarrhea and recurrent vomiting, \nwere assessed for the possibility of being treated as outpatients, based on their response to ondansetron, compared to a control \ngroup who did not receive ondansetron. The sample size was 100 for each group. Cases for the ondansetron group were under \nobservation for at least two hours in the emergency ward and were followed until 72 hours to find out if there was any need for \nthem to return to the hospital due to vomiting. Otherwise, all cases in the control group were hospitalized. Data of both groups, \nincluding the rate and duration of hospitalization, was analyzed. \nResults: Of the 100 individuals who received ondansetron (n = 91) 91% did not need to be hospitalized and 9 patients needed to be \nadmitted in the next 72 hours, while (n = 100) 100% of control group were hospitalized (P value = 0.003). Vomiting in the control \ngroup continued in 35% of patients after 72 hours of admission. The duration of hospitalization for the patients of the control group \nwas 2.94 ± 1.40 (mean ± SD) days. \nInterpretation:…
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.